This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Barbara Bartlik, MD
Department of Psychiatry Human Sexuality Program New York Hospital-Cornell Medical Center 525 E 68 St, Box 147 New York, NY 10021

Gregory Harmon, MD; Peter Kaplan, MD
New York

Arch Gen Psychiatry. 1997;54(2):188-189.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Methylphenidate hydrochloride (Ritalin), the drug of choice for attention-deficit hyperactivity disorder (ADHD), is contraindicated in patients with glaucoma on a theoretical, class-labeling basis. As methylphenidate had been, until recently, primarily prescribed to children, the consideration of prescribing it to patients with glaucoma rarely has arisen. However, as ADHD is being diagnosed and treated in more adults, this is becoming a treatment issue.

Moreover, stimulants are being used for the treatment of drug-induced and other sexual dysfunctions on an as-needed basis.^1-3 When used cautiously in conjunction with glaucoma medications and regular ophthalmologic monitoring, methylphenidate and other psychostimulants may be safe in patients with well-controlled, open-angle glaucoma. The following is an example, as well as a practical solution, to this problem.

Report of a Case.

A 55-year-old male writer with primary open-angle glaucoma was receiving methylphenidate hydrochloride, 25 mg per day, for ADHD. Although his IQ placed him in the gifted . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?